Biogen’s Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
The FDA approved Biogen Inc's (NASDAQ:
Oncolytics Biotech Announces Upcoming Oral Presentation On Randomized BRACELET-1 Trial In HR+/HER2- Metastatic Breast Cancer At The ASCO Annual Meeting
Oral presentation on BRACELET-1 to take place on June 3, 2023
Zai Lab Announces Presentation Of Results Of The LUNAR Phase 3 Clinical Trial In Non-Small Cell Lung Cancer At 2023 American Society Of Clinical Oncology Annual Meeting
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)))) today announced that the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023
Gracell Biotechnologies To Present Updated Clinical Data On BCMA/CD19 Dual-Targeting FasTCAR-T GC012F At 2023 ASCO Annual Meeting
Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell
Cullinan Oncology To Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, In Patients With Advanced Solid Tumors At ASCO 2023
Cullinan Oncology, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of
Immutep Announces Presentation Of New TACTI-002 Data At The 2023 ASCO Annual Meeting
Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented
SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE)
Allogene Therapeutics Announces Presentation Of Phase 1 Data From The ALLO-501/501A Trials In Large B Cell Lymphoma At The American Society Of Clinical Oncology Annual Meeting
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced it will present updated data
Theseus Pharmaceuticals Initial Dose Escalation Results From Ongoing Phase 1/2 Trial Of THE-630 Accepted For Online Publication At 2023 ASCO Annual Meeting
-- Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET --
CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX)
Geron Announces Upcoming Oral Presentation At 2023 American Society Of Clinical Oncology Annual Meeting Of Imetelstat Data From IMerge Phase 3 Lower Risk MDS Trial
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company's first-in-class telomerase inhibitor,
Biofrontera Inc. Announces Last Patient Out In Phase I Study To Evaluate Safety And Tolerability In Treating Actinic Keratosis Using 3 Tubes Of Ameluz(R)
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that that the last patient in a Phase I study to evaluate the safety and